| ||||
Public Act 096-1108 | ||||
| ||||
| ||||
AN ACT concerning public health.
| ||||
Be it enacted by the People of the State of Illinois,
| ||||
represented in the General Assembly:
| ||||
Section 1. Short title. This Act may be cited as the Lupus | ||||
Education and Awareness Act. | ||||
Section 5. Legislative findings and purpose. | ||||
(a) The General Assembly finds the following: | ||||
(1) Lupus is an urgent national health issue. Lupus is | ||||
the result of an immune system that is unbalanced and can | ||||
become destructive to any organ or tissue in the body. | ||||
Lupus is unpredictable and potentially fatal, yet no | ||||
satisfactory treatment exists. Its health consequences | ||||
include heart attacks, strokes, seizures, and organ | ||||
failure. | ||||
(2) National data indicates that more than 1.5 million | ||||
Americans live with some form of lupus; lupus affects women | ||||
9 times more often than men, and 80% of newly diagnosed | ||||
cases of lupus develop among women of childbearing age. An | ||||
estimated 65,000 people with lupus reside in Illinois. | ||||
(3) Lupus disproportionately affects women of color; | ||||
it is 2 to 3 times more common among African Americans, | ||||
Hispanics and Latinos, Asians, and Native Americans and is | ||||
generally more prevalent in minority populations, a health |
disparity that remains unexplained. | ||
(4) No new drugs have been approved by the U.S. Food | ||
and Drug Administration specifically for lupus in 50 years | ||
and, while current treatments for the disease can be | ||
effective, they can lead to damaging side effects. | ||
(5) The pain and fatigue associated with lupus can | ||
threaten one's ability to live independently, make it | ||
difficult to maintain employment, and lead normal lives. | ||
One in 5 people with lupus is disabled by the disease and | ||
consequently receives support from government programs, | ||
including Medicare, Medicaid, Social Security Disability, | ||
and Social Security Supplemental Income. | ||
(6) The estimated average annual total of direct and | ||
indirect costs for an individual with lupus is $21,000; for | ||
people who have the most serious form of lupus, medical | ||
costs can greatly exceed this amount, causing a significant | ||
economic, emotional, and social burden to the entire family | ||
and society. | ||
(b) The purpose of this Act is to create a multi-pronged, | ||
statewide program to promote public and health professional | ||
awareness among State and local health and human services | ||
officials, physicians, nurses, and other health care providers | ||
and increase knowledge concerning the causes and consequences | ||
of lupus, the importance of early diagnosis and appropriate | ||
management, and effective treatment and management strategies | ||
by taking the following actions: |
(1) Conducting educational and training programs for | ||
health professionals on lupus diagnosis and management.
| ||
(2) Disseminating medically sound educational | ||
materials and information on lupus research findings to | ||
patients and health care professionals.
| ||
(3) Fostering greater public understanding and | ||
awareness of lupus statewide.
| ||
Section 10. Definitions. For the purpose of this Act: | ||
"Department" means the Department of Public Health. | ||
"Director" means the Director of Public Health. | ||
"Panel" means the Interagency and Partnership Advisory | ||
Panel on Lupus. | ||
"Program" means the Lupus Education and Awareness Program | ||
(LEAP).
| ||
Section 15. Establishment of the Lupus Education and | ||
Awareness Program.
| ||
(a) Subject to appropriation, there is created within the | ||
Department of Public Health the Lupus Education and Awareness | ||
Program (LEAP). The Program shall be composed of various | ||
components, including, but not limited to, public awareness | ||
activities and professional education programs. Subject to | ||
appropriation, the Interagency and Partnership Advisory Panel | ||
on Lupus is created to oversee LEAP and advise the Department | ||
in implementing LEAP. |
(b) The Department shall establish, promote, and maintain | ||
the Lupus Education and Awareness Program with an emphasis on | ||
minority populations and at-risk communities in order to raise | ||
public awareness, educate consumers, and educate and train | ||
health professionals, human service providers, and other | ||
audiences. | ||
The Department shall work with a national organization that | ||
deals with lupus to implement programs to raise public | ||
awareness about the symptoms and nature of lupus, personal risk | ||
factors, and options for diagnosing and treating the disease, | ||
with a particular focus on populations at elevated risk for | ||
lupus, including women and communities of color. | ||
The Program shall include initiatives to educate and train | ||
physicians, health care professionals, and other service | ||
providers on the most up-to-date and accurate scientific and | ||
medical information regarding lupus diagnosis, treatment, | ||
risks and benefits of medications, research advances, and | ||
therapeutic decision making, including medical best practices | ||
for detecting and treating the disease in special populations. | ||
These activities shall include, but not be limited to, all of | ||
the following: | ||
(1) Distribution of medically-sound health information | ||
produced by a national organization that deals with lupus | ||
and government agencies, including, but not limited to, the | ||
National Institutes of Health, the Centers for Disease | ||
Control and Prevention, and the Social Security |
Administration, through local health departments, schools, | ||
agencies on aging, employer wellness programs, physicians | ||
and other health professionals, hospitals, health plans | ||
and health maintenance organizations, women's health | ||
programs, and nonprofit and community-based organizations. | ||
(2) Development of educational materials for health | ||
professionals that identify the latest scientific and | ||
medical information and clinical applications. | ||
(3) Working to increase knowledge among physicians, | ||
nurses, and health and human services professionals about | ||
the importance of lupus diagnosis, treatment, and | ||
rehabilitation.
| ||
(4) Support of continuing medical education programs | ||
presented by the leading State academic institutions by | ||
providing them with the most up-to-date information.
| ||
(5) Providing statewide workshops and seminars for | ||
in-depth professional development regarding the care and | ||
management of patients with lupus in order to bring the | ||
latest information on clinical advances to care providers.
| ||
(6) Development and maintenance of a directory of | ||
lupus-related services and lupus health care providers | ||
with specialization in services to diagnose and treat | ||
lupus. The Department shall disseminate this directory to | ||
all stakeholders, including, but not limited to, | ||
individuals with lupus, families, and representatives from | ||
voluntary organizations, health care professionals, health |
plans, and State and local health agencies. | ||
(c) The Director shall do all of the following: | ||
(1) Designate a person in the Department to oversee the | ||
Program.
| ||
(2) Identify the appropriate entities to carry out the | ||
Program, including, but not limited to, the following: | ||
local health departments, schools, agencies on aging, | ||
employer wellness programs, physicians and other health | ||
professionals, hospitals, health plans and health | ||
maintenance organizations, women's health organizations, | ||
and nonprofit and community-based organizations.
| ||
(3) Base the Program on the most current scientific | ||
information and findings.
| ||
(4) Work with governmental entities, community and | ||
business leaders, community organizations, health care and | ||
human service providers, and national, State, and local | ||
organizations to coordinate efforts to maximize State | ||
resources in the areas of lupus education and awareness.
| ||
(5) Use public health institutions for dissemination | ||
of medically sound health materials.
| ||
(d) The Department shall establish and coordinate the | ||
Interagency and Partnership Advisory Panel on Lupus consisting | ||
of 15 members, one of whom shall be appointed by the Director | ||
as the chair.
The Panel shall be composed of: | ||
(1) at least 3 individuals with lupus;
| ||
(2) three representatives from relevant State agencies |
including the Department;
| ||
(3) three scientists with experience in lupus who | ||
participate in various fields of scientific endeavor, | ||
including, but not limited to, biomedical research, | ||
social, translational, behavioral, and epidemiological | ||
research, and public health;
| ||
(4) two medical clinicians with experience in treating | ||
people with lupus; and
| ||
(5) four representatives from relevant nonprofit | ||
women's and health organizations, including one | ||
representative from a national organization that deals | ||
with the treatment of lupus. | ||
Individuals and organizations may submit nominations to | ||
the Director to be named to the Panel. Such nominations may | ||
include the following: | ||
(i) representatives from appropriate State departments | ||
and agencies, such as entities with responsibility for | ||
health disparities, public health programs, education, | ||
public welfare, and women's health programs; | ||
(ii) health and medical professionals with expertise | ||
in lupus; and | ||
(iii) individuals with lupus, and recognized experts | ||
in the provision of health services to women, lupus | ||
research, or health disparities. | ||
All members of the panel shall serve terms of 2 years. A | ||
member may be appointed to serve not more than 2 terms, whether |
or not consecutive.
A majority of the members of the panel | ||
shall constitute a quorum. A majority vote of a quorum shall be | ||
required for any official action of the Panel.
The Panel shall | ||
meet at the call of the chair, but not less than 2 times per | ||
year. All members shall serve without compensation, but shall | ||
be entitled to actual, necessary expenses incurred in the | ||
performance of their business as members of the Panel in | ||
accordance with the reimbursement polices for the State. | ||
Section 20. Funding. Subject to the availability of funds, | ||
the Department may make expenditures of up to $2,500 for fiscal | ||
year 2010 for use toward providing educational materials to | ||
clinics serving a high percentage of minorities in this State. | ||
The Director may accept grants, services, and property from the | ||
federal government, foundations, organizations, medical | ||
schools, and other entities as may be available for the | ||
purposes of fulfilling the obligations of this Program. Any | ||
such funds shall only supplement any appropriations made for | ||
the implementation of this Act. The Director shall seek any | ||
federal waiver or waivers that may be necessary to maximize | ||
funds from the federal government to implement the Program. | ||
Section 25. Staffing. The Department of Public Health shall | ||
provide staffing and administrative support for the | ||
implementation of the provisions of this Act.
|